Global Neurology Academy

Unpacking the Genetics of Friedreich’s Ataxia
Unpacking the Genetics of Friedreich’s Ataxia
NeuroFrontiers
Unpacking the Genetics of Friedreich’s Ataxia
- Arnulf Koeppen, MD
Friedreich’s Ataxia: Impact of Frataxin Loss
Friedreich’s Ataxia: Impact of Frataxin Loss
NeuroFrontiers
Friedreich’s Ataxia: Impact of Frataxin Loss
- Arnulf Koeppen, MD
Next-Generation MS Care: The Promise of Cell-Based Therapeutics
Next-Generation MS Care: The Promise of Cell-Based Therapeutics
NeuroFrontiers
Next-Generation MS Care: The Promise of Cell-Based Therapeutics
- Mark Freedman, HBSc, MSc, MD, CSPQ, FAAN, FRCPC
Redefining gMG Management: FcRn Antagonists and the New Era of Precision Neurology
Redefining gMG Management: FcRn Antagonists and the New Era of Precision Neurology
CME/CE Virtual Event
Redefining gMG Management: FcRn Antagonists and the New Era of Precision Neurology
September 30, 2026
11:45 AM - 12:45 PM ET
CME/CE In-Person Event
Redefining gMG Management: FcRn Antagonists and the New Era of Precision Neurology
September 30, 2026
Orlando, Florida
Applying the 2024 McDonald Criteria: Real-World Impacts on MS Diagnosis
Applying the 2024 McDonald Criteria: Real-World Impacts on MS Diagnosis
NeuroFrontiers
Applying the 2024 McDonald Criteria: Real-World Impacts on MS Diagnosis
- Aaron Miller, MD
Proactive Pregnancy Planning and Reproductive Care in MS
Proactive Pregnancy Planning and Reproductive Care in MS
NeuroFrontiers
Proactive Pregnancy Planning and Reproductive Care in MS
- Riley Bove, MD, MMSc
Updates in MS Care: Key Topics at AAN 2026
Updates in MS Care: Key Topics at AAN 2026
NeuroFrontiers
Updates in MS Care: Key Topics at AAN 2026
- Aaron Miller, MD

Medical News

Medical News
Rapid Whole Genome Sequencing Boosts Neurologic Diagnosis
04/21/2026
Read more
Medical News
Acute Ischemic Stroke Prognosis Improved by LLM
04/21/2026
Read more
Medical News
GBM AGILE Phase II/III Bayesian Randomized Platform Trial
04/20/2026
Read more
Medical News
Plant Based Dietary Patterns and Alzheimer Disease Risk
04/20/2026
Read more

See more news

CME/CE

Target Locked in gMG: Why T2T Matters
Target Locked in gMG: Why T2T Matters
MinuteCE®
Target Locked in gMG: Why T2T Matters
1.00 program credit
- Christyn Edmundson, MD
- Gil I. Wolfe MD, FAAN
1.00 program credit
The IgG Clock: Redose Using IgG Kinetics
The IgG Clock: Redose Using IgG Kinetics
MinuteCE®
The IgG Clock: Redose Using IgG Kinetics
1.00 program credit
- Christyn Edmundson, MD
- Gil I. Wolfe MD, FAAN
1.00 program credit
Scorecards That Matter: Use MG-ADL, MG-MMT, QMG, QoL
Scorecards That Matter: Use MG-ADL, MG-MMT, QMG, QoL
MinuteCE®
Scorecards That Matter: Use MG-ADL, MG-MMT, QMG, QoL
1.00 program credit
- Christyn Edmundson, MD
1.00 program credit
Turning Flares Into Function: Flag Uncontrolled Disease
Turning Flares Into Function: Flag Uncontrolled Disease
MinuteCE®
Turning Flares Into Function: Flag Uncontrolled Disease
1.00 program credit
- Christyn Edmundson, MD
- Gil I. Wolfe MD, FAAN
1.00 program credit

Clinical Practice

Is Friedreich’s Ataxia Developmental or Degenerative?
Is Friedreich’s Ataxia Developmental or Degenerative?
NeuroFrontiers
Is Friedreich’s Ataxia Developmental or Degenerative?
- Arnulf Koeppen, MD
SPOTLIGHT Registry Findings on Eculizumab and Ravulizumab in gMG
SPOTLIGHT Registry Findings on Eculizumab and Ravulizumab in gMG
NeuroFrontiers
SPOTLIGHT Registry Findings on Eculizumab and Ravulizumab in gMG
RAISE Subgroup Analysis: Zilucoplan Without Prior Rescue Therapy in gMG
RAISE Subgroup Analysis: Zilucoplan Without Prior Rescue Therapy in gMG
NeuroFrontiers
RAISE Subgroup Analysis: Zilucoplan Without Prior Rescue Therapy in gMG
Omaveloxolone in Friedreich’s Ataxia: Early Real-World Signals
Omaveloxolone in Friedreich’s Ataxia: Early Real-World Signals
NeuroFrontiers
Omaveloxolone in Friedreich’s Ataxia: Early Real-World Signals

Programs

Advances in Cell-Based Therapy for MS
Advances in Cell-Based Therapy for MS
NeuroFrontiers
Advances in Cell-Based Therapy for MS
- Mark Freedman, HBSc, MSc, MD, CSPQ, FAAN, FRCPC
Challenging the Status Quo in Schizophrenia Treatment
Challenging the Status Quo in Schizophrenia Treatment
On the Frontlines of Schizophrenia
Challenging the Status Quo in Schizophrenia Treatment
- Shelina Ramnarine, PhD
- Stephen Marder, MD
Addressing Social and Systemic Barriers in Schizophrenia
Addressing Social and Systemic Barriers in Schizophrenia
On the Frontlines of Schizophrenia
Addressing Social and Systemic Barriers in Schizophrenia
- Shelina Ramnarine, PhD
- Margaret Emerson, DNP, APRN, PMHNP-BC
Advancing Pediatric MS Care: Insights from AAN 2026
Advancing Pediatric MS Care: Insights from AAN 2026
NeuroFrontiers
Advancing Pediatric MS Care: Insights from AAN 2026
- Elizabeth Wilson, MD